EvolveImmune Therapeutics, Inc.
Industry
- Pharmaceuticals
- Biotechnology
See more in Biomedtracker
Latest on EvolveImmune Therapeutics, Inc.
Scrip
• By Joseph Haas
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Oak Hill Licenses Roche’s Rugonersen,
Scrip
• By Mandy Jackson
The end of 2023 is proving no different from the end of any other year, with venture capital firms and biopharmaceutical companies closing out a flurry of new VC funds and financings before December d
Scrip
• By Ayisha Sharma
EvolveImmune Therapeutics, Inc. is leveraging its proprietary EVOLVE platform to develop three-pronged T cell engagers that could reduce immune evasion by tumor cells via CD2 activation, with an init